[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Kawai A, Hasizume H, Sugihara S, Morimoto Y, Inoue H: Treatment of bone and soft tissue sarcomas of the hand and wrist. Int Orthop; 2002;26(1):26-30
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bone and soft tissue sarcomas of the hand and wrist.
  • We studied 13 consecutive patients with bone and soft tissue sarcomas of the hand and wrist.
  • Adjuvant therapy for nine patients consisted of chemotherapy in five and chemotherapy with radiation in four.
  • Our study indicates that treatment consisting of resection of these tumours with either a wide margin or a marginal margin followed by adjuvant radiation appeared to be safe and resulted in an acceptable degree of limb function except in the patients with epithelioid sarcoma.
  • [MeSH-major] Bone Neoplasms / surgery. Hand. Sarcoma / surgery. Soft Tissue Neoplasms / surgery. Wrist
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11954844.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3620853
  •  go-up   go-down


2. Ozcanli H, Ozdemir H, Ozenci AM, Söyüncü Y, Aydin AT: [Metastatic tumors of the hand in three cases]. Acta Orthop Traumatol Turc; 2005;39(5):445-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic tumors of the hand in three cases].
  • Metastatic malignancies of the hand are rare and they usually develop from lung, breast, and kidney tumors.
  • Metastases to the bones of the hand can cause pain, swelling, soft tissue ulceration, and osteolytic destruction.
  • We presented three patients with metastatic tumors of the hand, whose ages were 58 (male), 42 (female), and 40 (male) years.
  • Metastases developed in the thumb and the big toe, metacarpal bone, and the nail bed following treatment for primary tumors of the bladder, colon, and chondrosarcoma of the proximal femur, respectively.
  • One patient underwent amputation of the thumb and the big toe followed by systemic chemotherapy, one patient with metacarpal involvement was treated with Ray amputation, and the latter underwent a biopsy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bone Neoplasms / diagnosis. Hand
  • [MeSH-minor] Adult. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531705.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 25
  •  go-up   go-down


3. Casanova M, Ferrari A, Collini P, Bisogno G, Alaggio R, Cecchetto G, Gronchi A, Meazza C, Garaventa A, Di Cataldo A, Carli M, Italian Soft Tissue Sarcoma Committee: Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer; 2006 Feb 1;106(3):708-17
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee.
  • BACKGROUND: Epithelioid sarcoma (ES) is an uncommon malignant soft tissue tumor.
  • To the authors' knowledge, little information is available to date concerning its clinical features and management in children and adolescents, particularly with regard to the recently described proximal-type variant.
  • The current study concerns 30 patients age<18 years who were enrolled in the Italian Soft Tissue Sarcoma Committee protocols.
  • METHODS: Histopathologic specimens, clinical data, and treatment modalities were reviewed for the current analysis.
  • Nineteen patients had classic ES and 11 had proximal-type ES.
  • Surgery was the mainstay of treatment; radiotherapy was given to six patients considered to be at risk of local disease recurrence due to incomplete resection, and chemotherapy was administered to eight patients.
  • Local disease recurrence was the major cause of treatment failure.
  • Initially unfavorable clinical findings and a worse outcome were associated with the proximal-type variant of ES.
  • A response to chemotherapy was noted in three of the seven patients with measurable disease.
  • CONCLUSIONS: The current study confirms some typical features of ES (i.e., the peculiar superficial distal location [i.e., the hand, fingers], indolent growth, and a tendency to recur locally).
  • Further studies are needed to better define the clinical behavior and biology of the proximal-type variant of ES.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 16353216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Del Frari B, Zelger BG, Piza-Katzer H: [Epithelioid sarcoma of the hand, a seldomly recognized tumor]. Handchir Mikrochir Plast Chir; 2004 Oct;36(5):313-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid sarcoma of the hand, a seldomly recognized tumor].
  • [Transliterated title] Das Epithelioidsarkom der Hand, selten primär richtig diagnostiziert.
  • BACKGROUND: The epithelioid sarcoma of the hand is often misdiagnosed.
  • The characteristic histopathology is helpful in establishing the correct diagnosis.
  • Differential diagnosis includes synovialoma, fibromatosis and Dupuytren's contracture.
  • PATIENTS AND METHOD: Three young patients (one male and two female) were operated on the hand for treatment of Dupuytren's contracture, synovialoma and fibromas, respectively.
  • The original diagnosis having been found to be incorrect, the correct diagnosis was established namely, epithelioid sarcoma.
  • None of the patients underwent adjuvant radio- or chemotherapy.
  • Adequate treatment requires early radical excision; amputation may be required if the primary tumor is located in the fingers or treatment of recurrent growth.
  • Patients must be monitored with yearly lung X-rays since recurrence or metastasis may occur many years after the initial diagnosis and treatment.
  • [MeSH-major] Hand / surgery. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Amputation. Biopsy. Child. Connective Tissue / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Muscle, Skeletal / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503263.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • On the other hand, for early staged tumors of the larynx and pharynx, transoral laser microsurgery has become an effective means of local control of these lesions.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


6. Müller M, Bickert B, Germann G, Sauerbier M: [Soft-tissue sarcoma of the forearm and hand. Plastic surgical management]. Chirurg; 2008 Jul;79(7):682-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft-tissue sarcoma of the forearm and hand. Plastic surgical management].
  • [Transliterated title] Weichgewebesarkome an Unterarm und Hand. Plastisch-chirurgische Behandlung.
  • Radical tumor resection (R0) is the main therapeutic goal in the treatment of sarcomas of the forearm and hand.
  • Sophisticated reconstructive techniques are required with the forearm and hand.
  • Twenty patients with soft-tissue sarcomas of the hand and forearm were treated in our department between January 1995 and January 2005.
  • Ten patients received radiation and four got chemotherapy (two with neoadjuvant chemotherapy).
  • The average follow-up-time was 42 months.
  • These results show the necessity of plastic surgical reconstruction of the forearm and hand as an integral component of modern sarcoma therapy.
  • Multidisciplinary cooperation is mandatory for adequate treatment.
  • [MeSH-major] Forearm / surgery. Hand / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Limb Salvage. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Surgical Flaps

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Aug 15;95(4):852-61 [12209730.001]
  • [Cites] Acta Radiol. 1999 Jan;40(1):64-8 [9973905.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2719-25 [12860950.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Chirurg. 1993 Jul;64(7):517-26 [8375201.001]
  • [Cites] Plast Reconstr Surg. 1998 Aug;102(2):442-7 [9703082.001]
  • [Cites] AJR Am J Roentgenol. 1988 Mar;150(3):615-20 [3257620.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] Radiology. 1993 Feb;186(2):455-9 [8421750.001]
  • [Cites] Clin Orthop Relat Res. 2005 Feb;(431):193-200 [15685075.001]
  • [Cites] J Hand Surg Br. 2002 Dec;27(6):573-6 [12475519.001]
  • [Cites] Cancer. 1952 Sep;5(5):975-8 [12988186.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):499-521 [12916466.001]
  • [Cites] J Bone Joint Surg Am. 1995 Apr;77(4):564-71 [7713973.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):453-64 [14585226.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1165-73 [15368057.001]
  • [Cites] J Bone Joint Surg Am. 1988 Jul;70(6):862-70 [3392084.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S4-8 [12042982.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):921-7 [15466352.001]
  • [Cites] Chirurg. 1997 Dec;68(12):1309-17 [9483362.001]
  • [Cites] Plast Reconstr Surg. 2004 Aug;114(2):400-8; discussion 409-10 [15277806.001]
  • [Cites] Arch Surg. 1992 Nov;127(11):1285-9 [1444788.001]
  • [Cites] Plast Reconstr Surg. 2005 Dec;116(7):1918-25 [16327604.001]
  • [Cites] Curr Oncol Rep. 2003 Jul;5(4):274-81 [12781068.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1997;114:164-7 [9574119.001]
  • [Cites] Am J Ind Med. 1996 Jun;29(6):602-8 [8773720.001]
  • [Cites] Plast Reconstr Surg. 2006 Aug;118(2):443-54; discussion 455-6 [16874216.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):480-8 [3819810.001]
  • [Cites] Chirurg. 2003 Apr;74(4):370-4 [12719879.001]
  • [Cites] Cancer. 1976 Dec;38(6):2390-400 [137071.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1051-8 [1471725.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1491-500 [3047339.001]
  • (PMID = 18437325.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL: Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int; 2009 Jun;103(12):1636-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 24 patients, 21 had previous chemotherapy with docetaxel.
  • All patients had bony metastases, either alone (in 11) or with soft-tissue disease (in 13).
  • Most frequent toxicities included hand-foot skin reaction (grade 2 in nine patients, grade 3 in three), rash, abnormalities in liver function tests, and fatigue.
  • CONCLUSIONS: Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2178-85 [18445842.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5472-80 [16061863.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1688-94 [16006586.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] Urology. 2006 Jun;67(6):1235-40 [16765185.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):556-63 [17577218.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1480-5 [18040273.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):209-14 [18172272.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):521-6 [18085595.001]
  • [Cites] J Pharm Biomed Anal. 2008 Jan 22;46(2):362-7 [18309574.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1148-59 [18309951.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):746-51 [18056648.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • (PMID = 19154507.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006538-15
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 33515-09-2 / Gonadotropin-Releasing Hormone; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / raf Kinases
  • [Other-IDs] NLM/ NIHMS164017; NLM/ PMC2818665
  •  go-up   go-down


8. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin; 2004 Aug;20(3):325-33, vii
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma of the upper extremity.
  • Soft tissue sarcomas of the upper extremities are rare and hand surgeons typically encounter only one or two undiagnosed soft tissue sarcomas during their careers.
  • It is incumbent on the physician to review repeatedly the characteristics of these tumors and remain suspicious, because these lesions typically are misdiagnosed and treatment is delayed.
  • The most common soft tissue sarcomas of the upper extremity are the epithelioid sarcoma, synovial cell sarcoma, and malignant fibrous histiocytoma.
  • Limb salvage surgery is the treatment of choice for soft tissue sarcomas to preserve upper extremity function.
  • Following wide tumor resection, adjuvant therapies such as chemotherapy, external beam radiation therapy, and brachytherapy may lessen local recurrence rates, but their effect on overall survival remains unclear.
  • [MeSH-major] Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Arm. Biopsy. Chemotherapy, Adjuvant. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Humans. Liposarcoma / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275691.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


9. Li SF, Wang X, Wang C, He LH, Shi YH, Hao CF, Dong GL, Tong ZS: [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):944-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
  • OBJECTIVE: To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer.
  • The median time to progression (TTP) was 5.6 months.
  • The effective cases in different metastatic organs were: 8 cases in the lung, 6 cases in the liver, 3 cases in the soft tissue and 3 cases in the lymph nodes.
  • The common adverse reactions were myelosuppression, hand-foot syndrome, nausea and vomiting.
  • Two patients developed degree IV myelosuppression.
  • CONCLUSION: The combination chemotherapy regimen of docetaxel plus capecitabine is well-tolerated and effective for anthracycline-resistant metastatic breast cancer.
  • [MeSH-major] Anthracyclines / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174000.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Pierlot A, Calteux N, Mataigne F, Colette JM: [Soft tissue sarcomas of the hand: report of a radiation-induced case]. Ann Chir Plast Esthet; 2001 Feb;46(1):45-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcomas of the hand: report of a radiation-induced case].
  • [Transliterated title] Les sarcomes des tissus mous de la main. A propos d'un cas de sarcome radio-induit.
  • Soft tissue sarcoma surgery is based on techniques that are in the process of ongoing development.
  • In this study, the case is reported of a female patient who was operated on at the age of 14 years for a primary synoviosarcoma of the dominant hand, which was treated by conservative surgery and 60 Gy adjuvant radiotherapy.
  • Amputation of the distal third of the forearm was performed.
  • All the distinct diagnostic criteria were met, i.e., a latency of over two years, different diagnosis and the appearance of the tumor within (or next to) the irradiated field.
  • Two main factors should be taken into account in treatment strategy: i) distant metastases of high-grade soft tissue sarcomas often appear early in the course of the disease, and are not affected by surgery at the primary site;.
  • Technical progress and a multidisciplinary approach have resulted in more sophisticated treatment (allowing a larger surgical resection area, and better residual function).
  • Surgical management remains the treatment of choice, as radiotherapy and chemotherapy have not demonstrated any positive effect on patient survival.
  • [MeSH-major] Forearm. Hand. Histiocytoma, Benign Fibrous / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Sarcoma, Synovial / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Amputation. Biopsy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Survival Analysis. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11233734.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


11. Puhaindran ME, Athanasian EA: Malignant and metastatic tumors of the hand. J Hand Surg Am; 2010 Nov;35(11):1895-900; quiz 1900
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant and metastatic tumors of the hand.
  • Malignant tumors of the hand are rare, although there remain many instances in which marginal excisions are performed for unsuspected malignant hand lesions.
  • This article provides an update for the current management of patients with primary malignant and metastatic tumors of the hand, including the roles of adjuvant radiotherapy and chemotherapy for the more common hand tumors.
  • [MeSH-major] Bone Neoplasms / therapy. Hand. Neoplasm Invasiveness / pathology. Sarcoma / therapy. Sentinel Lymph Node Biopsy / methods. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Education, Medical, Continuing. Female. Humans. Male. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • (PMID = 21050968.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


12. Vetter M, Germann G, Bickert B, Sauerbier M: Current strategies for sarcoma reconstruction at the forearm and hand. J Reconstr Microsurg; 2010 Sep;26(7):455-60
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current strategies for sarcoma reconstruction at the forearm and hand.
  • Multistructural reconstructive procedures are often required to achieve a sufficient reconstruction of the forearm and/or hand after radical tumor resection.
  • Clear margin (R0) resection is the main therapeutic goal for the treatment of sarcomas.
  • In our department, 20 patients with soft tissue sarcomas of the hand/forearm were treated between 1995 and 2005.
  • The average follow-up time was 42 months.
  • The most common tumor type was the myxoid fibrous histiocytoma in 10 cases.
  • Ten patients received radiation and four obtained chemotherapy postoperatively (two patients received neoadjuvant chemotherapy).
  • Our results show the necessity of plastic-surgical reconstruction of the forearm and hand as an integrative component of modern sarcoma therapy.
  • It can be concluded that plastic-surgical reconstruction of the extremity plays a key role within the multimodal concept of therapy for patients with sarcoma at the forearm and hand.
  • [MeSH-major] Forearm / surgery. Hand / surgery. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Surgical Flaps / blood supply
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Child, Preschool. Combined Modality Therapy. Disability Evaluation. Female. Fibula / transplantation. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Humans. Infant. Limb Salvage. Male. Microsurgery / methods. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Thieme Medical Publishers.
  • (PMID = 20458673.001).
  • [ISSN] 1098-8947
  • [Journal-full-title] Journal of reconstructive microsurgery
  • [ISO-abbreviation] J Reconstr Microsurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Daigeler A, Kuhnen C, Moritz R, Stricker I, Goertz O, Tilkorn D, Steinstraesser L, Steinau HU, Lehnhardt M: Lymph node metastases in soft tissue sarcomas: a single center analysis of 1,597 patients. Langenbecks Arch Surg; 2009 Mar;394(2):321-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastases in soft tissue sarcomas: a single center analysis of 1,597 patients.
  • PURPOSE: The aim of this study was to examine the clinical course of patients with the rare finding of regional lymph node metastasis (RLNM) from soft tissue sarcoma.
  • MATERIALS AND METHODS: Data from 28 out of 1,597 consecutive soft tissue sarcoma patients with RLNM were from the patients' charts and interviewing patients and general practitioners.
  • Survival was independent from surgical resection status of the primary tumor and the RLNM as well as from adjuvant radiation and chemotherapy.
  • Tumor entity as well as the length of the time period from primary to RLNM affect survival.
  • CONCLUSIONS: Surgical treatment as well as radiation and chemotherapy may improve survival in selected cases but probably have their value much more in terms of local disease control and improvement life quality of patients who probably already suffer from an aggressive systemic disease at time of nodal involvement.
  • [MeSH-major] Lymphatic Metastasis / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy, Adjuvant. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1975 Nov;182(5):597-602 [1190864.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):714-9 [15231526.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):601-12 [3559651.001]
  • [Cites] Ann Surg. 1999 May;229(5):602-10; discussion 610-2 [10235518.001]
  • [Cites] Eur J Surg Oncol. 1988 Apr;14(2):151-6 [3360156.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2004 Jun 7;42(11):678-82 [15329259.001]
  • [Cites] Arch Surg. 1983 Aug;118(8):915-8 [6307217.001]
  • [Cites] J Thorac Cardiovasc Surg. 1965 Mar;49:357-63 [14265951.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):688-90 [10762739.001]
  • [Cites] Surg Oncol. 2003 Nov;12(3):201-6 [12957624.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):999-1006 [3409181.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1800-8 [3308055.001]
  • [Cites] Ann Surg Oncol. 2000 Apr;7(3):218-25 [10791853.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):491-5 [9309338.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):129-34 [15346063.001]
  • [Cites] Cancer. 1977 Oct;40(4):1562-70 [907970.001]
  • [Cites] Surgery. 1978 Aug;84(2):231-40 [278229.001]
  • [Cites] Cancer. 1974 Mar;33(3):888-97 [4815588.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):996-9 [16672185.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):675-82 [8616759.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Am J Surg. 1980 Jul;140(1):9-16 [6930823.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Jan;5(1):121-7 [8789497.001]
  • [Cites] Chirurg. 2005 May;76(5):493-500 [15827707.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):16-20 [11344475.001]
  • [Cites] Semin Surg Oncol. 1988;4(1):27-9 [2832923.001]
  • [Cites] Cancer. 1987 Aug 15;60(4):910-5 [3297302.001]
  • [Cites] Praxis (Bern 1994). 1998 Aug 19;87(34):1061-5 [9757789.001]
  • [Cites] Ann Surg. 1993 Jan;217(1):72-7 [8424704.001]
  • (PMID = 18594854.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Jayakumar S, Jatavalabulla S, Miller IM: Peripheral primitive neuroectodermal tumour of the hand in an adult. J Hand Surg Eur Vol; 2007 Aug;32(4):460-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumour of the hand in an adult.
  • We present a case of a 28 year-old woman who presented with a peripheral primitive neuroectodermal tumour of the right hand involving the fifth metacarpal and little finger.
  • Initial radiological staging did not reveal metastasis but, after recurrence locally at two years and in spite of adjuvant chemotherapy and radiotherapy, the patient died of progressive metastatic disease 4 years later.
  • [MeSH-major] Hand / surgery. Neuroectodermal Tumors, Primitive / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Humans. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950200.001).
  • [ISSN] 1753-1934
  • [Journal-full-title] The Journal of hand surgery, European volume
  • [ISO-abbreviation] J Hand Surg Eur Vol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Matsumoto S, Kawaguchi N, Manabe J, Tanizawa T, Koyama S, Ae K, Shimoji T: [Surgical treatment for bone and soft tissue sarcoma]. Gan To Kagaku Ryoho; 2004 Sep;31(9):1314-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for bone and soft tissue sarcoma].
  • There are many kinds of wide excision or wide resection, which are methods to remove the tumor with surrounding tissues.
  • The curability of wide resection depends on the range and characteristics of the normal surrounding tissues.
  • The so-called "Safety surgical margin" is the margin that prevents local recurrence due to insufficient surgical treatment.
  • Local recurrence due to other causes can not be treated by surgery alone as chemotherapy is also required.
  • For example, the infiltrative type of malignant fibrous histiocytoma requires a curative procedure.
  • On the other hand, non-infiltrative types of sarcoma or high-grade sarcoma, which are good responders to preoperative treatment, are locally controlled by an adequate wide margin procedure.
  • Once postoperative complications occur, patients must remain in the hospital for a long time.
  • To prevent this, the preservation of normal tissue, meaning reduction of surgical margin, is important.
  • [MeSH-major] Bone Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Blood Vessel Prosthesis Implantation. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Quality of Life. Surgical Procedures, Operative / methods. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15446549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 6
  •  go-up   go-down


16. Leit ME, Tomaino MM: Principles of limb salvage surgery of the upper extremity. Hand Clin; 2004 May;20(2):v, 167-79
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goals of limb salvage surgery in the upper extremity are to achieve resection of the tumor and preserve hand function without the risk for local recurrence.
  • Historically, amputation was the treatment of choice for a neoplasm of the hand, wrist, and forearm, but limb-sparing procedures have become feasible largely because of advances in diagnostic imaging, reconstructive microsurgery, and adjuvant radiotherapy and chemotherapy.
  • Because preservation of hand function, even modest levels thereof, is clearly superior to amputation from a functional standpoint, the authors review the principles of limb salvage in this article.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Bone Transplantation. Fibula / transplantation. Forearm. Giant Cell Tumor of Bone / surgery. Hand. Humans. Prostheses and Implants. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15201022.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


17. Li L, Cen S, Huang F: [Clinical research on 11 cases of epithelioid sarcoma]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Dec;21(12):1315-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical features, diagnosis, and treatment of patients with localized epithelioid sarcoma (ES).
  • Seven patients underwent an expanding resection surgery, and the tumors with the surrounding normal tissues 3 cm above were removed.
  • All the patients underwent routine radiotherapy and chemotherapy after operation.
  • They did not have a further surgical treatment.
  • CONCLUSION: An early expanding resection surgery combined with postoperative chemotherapy and radiotherapy is the therapy of choice for treating ES.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / surgery. Surgical Flaps. Upper Extremity / surgery
  • [MeSH-minor] Adolescent. Adult. Amputation. Bone Transplantation. Female. Hand / pathology. Hand / surgery. Humans. Lower Extremity / pathology. Lower Extremity / surgery. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Soft Tissue Injuries / surgery. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277674.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Kim HK, Jin SY, Lee NS, Won JH, Park HS, Yang WI: Posttransplant primary cutaneous Ki-1 (CD30)+/CD56+ anaplastic large cell lymphoma. Arch Pathol Lab Med; 2004 Aug;128(8):e96-9
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite reduction in the dose of immunosuppression and localized radiotherapy, the tumor had rapidly progressed to involve the soft tissue of the right hand.
  • Systemic chemotherapy induced complete regression of the soft tissue lesion.
  • This case illustrates that posttransplant primary cutaneous CD30+ anaplastic large cell lymphomas may assume an aggressive clinical course but can still be controlled by systemic chemotherapy.
  • [MeSH-minor] Antigens, CD56 / analysis. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Azathioprine / administration & dosage. Azathioprine / adverse effects. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / pathology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Cyclosporine / adverse effects. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prednisolone / adverse effects. Remission Induction. Vincristine / administration & dosage


19. Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, Lise M: Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am; 2003 Jul;12(3):781-94
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraperitoneal chemotherapy, mainly when performed during HIIC after cytoreductive surgery, is considered potentially curative for the treatment of solid tumors with spread to the peritoneal surface.
  • When selecting antiblastic agents to be administered intraperitoneally, it is important to bear in mind that a low lipophility and a high molecular weight are the ideal drug characteristics.
  • Drugs with these features allow a favorable ratio to be achieved between peritoneal and plasma concentrations, due to the reduced tendency to diffuse through the plasma-peritoneal barrier, even after extensive removal of the peritoneum.
  • Moreover, a low rate of diffusion through the tumor capillaries implies a low rate of drug clearance, with a higher intratumoral drug accumulation.
  • Among the drugs used so far for intraperitoneal chemotherapy, the combination of CDDP and DXR appears to be one of the most effective available regimens with acceptable local-regional toxicity.
  • In our clinical experience with this drug combination, DXR showed a much more advantageous plasma/peritoneal AUC ratio than CDDP (162 +/- 113 and 20 +/- 6, respectively).
  • On the other hand, it has been demonstrated that very high intraperitoneal concentrations of CDDP can be achieved without incurring significant systemic toxicity by using intravenous injection of sodium thiosulphate during HIIC.
  • Following experimental and clinical results of TNF alpha-based isolated limb perfusion for locally advanced soft tissue sarcoma or melanoma, greater efforts are being made to exploit the potential effect of this cytokine used in association with hyperthermia and other drugs (i.e., CDDP and DXR) suitable for intraperitoneal infusion/perfusion.
  • However, it is not yet clear whether the observed effect of TNF alpha on the peritoneal-plasma barrier, which seems to favor the passage of both drugs into the systemic circulation, is overcome by the positive effect of this agent on drug penetration into tumor.
  • Further pharmacologic studies should be undertaken to clarify whether or not these interactions will be of benefit to the patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Carcinoma / drug therapy. Infusions, Parenteral. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Biological Availability. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Intraoperative Period. Male. Maximum Tolerated Dose. Neoplasm Staging. Peritoneum / drug effects. Peritoneum / surgery. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14567031.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 50
  •  go-up   go-down


20. Rodriguez-Galindo C, Ramsey K, Jenkins JJ, Poquette CA, Kaste SC, Merchant TE, Rao BN, Pratt CB, Pappo AS: Hemangiopericytoma in children and infants. Cancer; 2000 Jan 01;88(1):198-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemangiopericytoma (HPC) is a soft-tissue neoplasm most commonly seen in adults; only 5-10% of cases occur in children.
  • METHODS: The authors reviewed the clinicopathologic features of HPC as well as the treatment and outcomes of the 12 children (9 males and 3 females) treated for this disease at St. Jude Children's Research Hospital over a 35-year period.
  • RESULTS: At diagnosis, 9 patients were older than 1 year and 3 were younger than 1 year.
  • One patient had metastatic disease at diagnosis, and three had unresectable tumors.
  • Two patients experienced objective responses to chemotherapy.
  • Among the three infants, two had unresectable disease at diagnosis, and both experienced excellent responses to neoadjuvant chemotherapy.
  • In one case, the response of the tumor to chemotherapy correlated with maturation to hemangioma.
  • CONCLUSIONS: HPC in children older than 1 year does not differ from adult HPC, and aggressive multimodality therapy is required.
  • Infantile HPC, on the other hand, is characterized by better clinical behavior, with documented chemoresponsiveness and spontaneous regression, and requires a more conservative surgical approach.
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Medical Records. Neoplasm Staging. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10618624.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / PHS HHS / / LA-23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA: Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol; 2010 Feb 20;28(6):976-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer.
  • Treatment-related grade 3 hand-foot syndrome (17% v < 1%) and grade 3/4 diarrhea (11% v 4%) occurred more commonly with HTX than HT.
  • CONCLUSION HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Receptor, ErbB-2 / metabolism. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. In Situ Hybridization, Fluorescence. International Agencies. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage. Trastuzumab. Treatment Outcome. Young Adult


22. Ogawa K, Toita T, Kakinohana Y, Adachi G, Kojya S, Itokazu T, Shinhama A, Matsumura J, Murayama S: Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep; 2001 Mar-Apr;8(2):315-9
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective study was conducted to analyze the local control and late complications in patients with squamous cell carcinoma of the maxillary sinus treated with postoperative radiation therapy following surgery.
  • Sixteen patients received preoperative intraarterial chemotherapy.
  • The total dose to the primary tumor bed was 40-70 Gy (median: 54 Gy) with a fraction size of 2 Gy.
  • The median follow-up time of the surviving patients was 93 months (range: 25-179 months).
  • For the patients with negative surgical margins, 8 of 9 (89%) patients achieved local control with a dose of 50-54 Gy, while 7 of 10 (70%) patients with microscopically positive margins achieved local control with a dose of 60-64 Gy.
  • There were 11 late complications found in 9 patients; bone necrosis in 2, soft tissue necrosis in 2, trisumus: 2, cellulitis in 1, retinopathy in 1, and vision impairment in 3 patients.
  • A total dose of 60 Gy or more was administered in all patients who suffered late complications except for 2 patients with vision impairment.
  • For patients with negative surgical margins, a total dose of 50-54 Gy in conventional fractionation was appropriate to achieve local control as well as to reduce late complications.
  • On the other hand, a dose of 60 Gy or more was required for the patients with microscopic positive margins.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Cellulitis / etiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Eye Diseases / epidemiology. Eye Diseases / etiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Necrosis. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Time Factors. Trismus / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11182047.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Albores-Zúñiga O, Padilla-Rosciano AE, Martínez-Said H, Cuéllar-Hubbe M, Ramírez-Bollas J: [Clear cell sarcoma and sentinel lymph node biopsy. Case report and literature review]. Cir Cir; 2006 Mar-Apr;74(2):121-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The procedure of sentinel node biopsy has been used previously in clear cell sarcoma.
  • Due to the similar biological features with melanoma, this procedure can be effective.
  • A 19-year-old man presented with ulcerated lesion in the fifth finger of the left hand.
  • The final report confirmed three metastasic nodes and the patient received adjuvant chemotherapy.
  • [MeSH-major] Sarcoma, Clear Cell / pathology. Sentinel Lymph Node Biopsy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Coloring Agents. Humans. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Neoplasm Staging / methods. Radiography, Thoracic. Staining and Labeling / methods. Technetium Compounds. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887085.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Technetium Compounds
  •  go-up   go-down


24. Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C, Dugan U, Norton L, Hudis C: Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol; 2008 Apr 10;26(11):1797-802
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study was conducted to determine, in patients with advanced-stage breast cancer, the maximum tolerated dose (MTD) of capecitabine administered orally for 7 days followed by a 7-day rest (7/7), a schedule based on a mathematical method for the optimization of anticancer drug scheduling.
  • There was no limit to number of prior treatments.
  • The most frequently reported treatment-related grade 2/3 adverse events were hand-foot syndrome (29%), leukopenia/neutropenia (24%), and fatigue (19%).
  • Three patients experienced grade 3 hand-foot syndrome; one of these patients had grade 3 diarrhea.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Carcinoma / secondary. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Models, Biological. Prodrugs / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Capecitabine. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Foot Dermatoses / chemically induced. Hand Dermatoses / chemically induced. Hematologic Diseases / chemically induced. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Maximum Tolerated Dose. Middle Aged. Soft Tissue Neoplasms / secondary. Thoracic Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 10;26(11):1781-2 [18398142.001]
  • (PMID = 18398145.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Yu SJ, Zhao ZG, Zang L, Lu HZ, Zhang HT, Xu L: [Clinical treatment and prognosis for clear cell sarcoma: analysis of 19 cases]. Zhonghua Yi Xue Za Zhi; 2008 Jun 3;88(21):1458-61
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical treatment and prognosis for clear cell sarcoma: analysis of 19 cases].
  • OBJECTIVE: To explore the clinical features, prognosis, and optimal treatment strategy of clear cell sarcoma (CCS).
  • 9, with histologically confirmed CCS, 3 with tumors > or =5 cm and 16 with tumors <5 cm, 5 tumors being located in the upper extremity, 2 in the hand, 6 in the lower extremity, 2 in the foot, 3 in the trunk, and 1 in the head, were hospitalized from March 1973 to March 2007.
  • Eight patients received chemotherapy, 8 radiotherapy and 1 combined chemotherapy and radiotherapy.
  • 3 patients developed lymph node metastasis and 2 developed pulmonary metastasis.
  • Of the 9 patients who did not undergo re-operation 7 developed lymph node metastasis, 6 developed pulmonary metastasis and 6 died.
  • CONCLUSION: CCS is a rare and high grade soft tissue sarcoma with high incidence rates of local recurrence and metastasis, and poor prognosis.
  • The role of chemotherapy and radiotherapy for CCS should be investigated further.
  • [MeSH-major] Sarcoma / therapy. Sarcoma, Clear Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953850.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Kronberger M: [Communication with palliative care patients: truth and hope--a contradiction?]. Wien Med Wochenschr; 2010 Jul;160(13-14):319-24
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Gespräche mit Palliativpatienten: Wahrheit und Hoffnung--ein Widerspruch?
  • On the other hand they have to accept the patients handling with given information and to respect that sometimes patients do not want to know the whole truth.
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Denial (Psychology). Disease Progression. Follow-Up Studies. Humans. Male. Neoadjuvant Therapy. Neoplasm Staging. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / psychology. Neoplasms, Second Primary / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / psychology. Soft Tissue Neoplasms / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2006 Nov;7(11):944-50 [17081920.001]
  • [Cites] Ann Oncol. 1997 Sep;8(9):857-63 [9358935.001]
  • [Cites] J Palliat Care. 1997 Autumn;13(3):29-33 [9354038.001]
  • [Cites] Wien Med Wochenschr. 2008;158(23-24):654-8 [19165442.001]
  • [Cites] Jpn J Clin Oncol. 2009 Apr;39(4):201-16 [19190099.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9 Suppl):49s-51s [12743192.001]
  • [Cites] J Pain Symptom Manage. 2007 Jul;34(1):81-93 [17531434.001]
  • [Cites] Cancer Pract. 1997 May-Jun;5(3):147-54 [9171550.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1278-88 [15718326.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9 Suppl):17s-19s [12743181.001]
  • [Cites] BMC Palliat Care. 2007 Jan 24;6:1 [17250767.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1105-13 [17914080.001]
  • (PMID = 20694759.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


27. Spicer J, Plunkett T, Somaiah N, Chan S, Kendall A, Bolunwu N, Pandha H: Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis; 2005;8(4):364-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Currently available treatment for hormone refractory prostate cancer is limited in efficacy and associated with significant toxicity.
  • Tumour response was assessed using serum PSA measurement at 3-weekly intervals and, where present, imaging of soft tissue metastases.
  • In seven other patients (50%), treatment decreased the rate of PSA rise.
  • Toxicity was significant but manageable, the most common adverse events being nausea, mucositis and hand-foot syndrome, each occurring in 50% of patients.
  • All toxicities were grade 1 or 2, except for grade 3 hand-foot syndrome occurring in one patient, and no dose reduction was required because of toxicity.
  • [MeSH-major] Androgens / pharmacology. Deoxycytidine / analogs & derivatives. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Capecitabine. Drug Resistance, Neoplasm. Fluorouracil / analogs & derivatives. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077679.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 3.4.21.77 / Prostate-Specific Antigen; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement